<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Most esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> arise within <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> but the cause of this increasingly prevalent condition remains unknown </plain></SENT>
<SENT sid="1" pm="."><plain>Early detection improves survival and discriminant screening markers for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> are needed </plain></SENT>
<SENT sid="2" pm="."><plain>This study was designed to explore the natural history of eyes absent 4 (EYA4) gene methylation in the <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and to evaluate methylated EYA4 as a candidate marker </plain></SENT>
<SENT sid="3" pm="."><plain>Aberrant promoter methylation of EYA4 was studied by methylation-specific PCR using <z:chebi fb="0" ids="17137">bisulfite</z:chebi>-treated DNA from esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and <z:mpath ids='MPATH_458'>normal</z:mpath> epithelia, and then confirmed by sequencing </plain></SENT>
<SENT sid="4" pm="."><plain>Eight <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines were treated with the demethylation agent <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi>, and EYA4 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression with and without treatment was quantified by real-time reverse-transcription PCR </plain></SENT>
<SENT sid="5" pm="."><plain>EYA4 hypermethylation was detected in 83% (33 of 40) of esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and 77% (27 of 35) of Barrett's tissues, but only in 3% (2 of 58) of <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal and gastric mucosa samples (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>The unmethylated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines had much higher EYA4 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression than the methylated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="7" pm="."><plain>Demethylation caused by <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> increased the <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression level by a median of 3.2-fold in methylated cells, but its effect on unmethylated cells was negligible </plain></SENT>
<SENT sid="8" pm="."><plain>Results indicate that aberrant promoter methylation of EYA4 is very common during <z:mp ids='MP_0002006'>tumorigenesis</z:mp> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, occurs in early <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, seems to be an important mechanism of down-regulating EYA4 expression, and represents an intriguing candidate marker for Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
</text></document>